Report #2873412

Received Nov 18, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: 36 yrs
State: NJ
Recovered: Unknown
Vaccinated: Nov 13, 2025
Onset: Nov 13, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (ENGERIX-B)	GLAXOSMITHKLINE BIOLOGICALS	2	CT3Z7	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

received the 2nd dose early: it was administered on 13/Nov/2025; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too short in a 36-year-old male patient who received HBV (Engerix B) (batch number CT3Z7, expiry date 13-FEB-2027) for prophylaxis. Concomitant products included Hepatitis b vaccine rHBsAg (yeast) (Engerix b). On 13-NOV-2025, the patient received the 2nd dose of Engerix B. On 13-NOV-2025, an unknown time after receiving Engerix B, the patient experienced drug dose administration interval too short (Verbatim: received the 2nd dose early: it was administered on 13/Nov/2025). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 13-Nov-2025